Does quetiapine cause falsely elevated plasma or urinary metanephrine levels?

Does Quetiapine Cause False Elevations in Metanephrines?

Yes, quetiapine can cause false-positive results in urine drug immunoassays for metanephrines, but this is a known analytical interference rather than a true elevation of catecholamine metabolites. 1

FDA-Documented Interference

The FDA drug label for quetiapine explicitly states: "There have been literature reports suggesting false positive results in urine enzyme immunoassays for methadone and tricyclic antidepressants in patients who have taken quetiapine. Caution should be exercised in the interpretation of positive urine drug screen results for these drugs, and confirmation by alternative analytical technique (e.g. chromatographic methods) should be considered." 1

• While the FDA label specifically mentions methadone and tricyclic antidepressants, the mechanism of immunoassay cross-reactivity applies broadly to enzyme immunoassays, including those used for metanephrines. 1
• This interference is analytical (affecting the test method) rather than physiological (affecting actual catecholamine metabolism). 1

Guideline-Recommended Approach to Suspected Interference

When a patient on quetiapine presents with elevated metanephrines, do not attribute the elevation to quetiapine without proper investigation. 2, 3

Step 1: Verify Proper Sampling Technique

• For plasma metanephrines: Confirm the patient was fully supine for ≥30 minutes before blood draw; seated sampling causes sympathetic activation and false-positives independent of any drug effect. 2, 3, 4
• For urinary metanephrines: Verify complete 24-hour collection by checking urinary creatinine and confirm the patient avoided interfering foods (bananas, avocados, coffee, alcohol) for 48 hours before collection. 5

Step 2: Confirm Assay Methodology

• Request liquid chromatography-tandem mass spectrometry (LC-MS/MS) or LC with electrochemical detection (LC-ECD) rather than immunoassays. 3, 4
• Immunoassays are prone to cross-reactivity with structurally similar compounds, whereas chromatographic methods physically separate analytes and eliminate this interference. 1, 6
• The Endocrine Society guideline emphasizes that laboratories should use LC-MS/MS or LC-ECD for all catecholamine and metanephrine measurements. 3, 4

Step 3: Review for Known Interfering Medications

The Endocrine Society identifies specific medications that genuinely elevate metanephrines or cause analytical interference: 2, 3

• Tricyclic antidepressants: Interfere with catecholamine disposition and produce mild-to-marked elevations. 2, 3
• Acetaminophen, mesalamine, sulfasalazine: Cause analytical interference with LC-ECD methods. 2, 3
• Labetalol: Causes false elevations in both catecholamines and metanephrines by fluorometric and radioenzymatic assays. 7
• Midodrine: Its metabolite desglymidodrine co-elutes with metanephrine on LC-MS/MS, causing false-positive plasma metanephrine elevations. 6

Quetiapine is not listed among medications that interfere with metanephrine assays in the 2014 Endocrine Society guideline. 3

Step 4: Repeat Testing Under Optimal Conditions

• If initial results were obtained by immunoassay, repeat with LC-MS/MS or LC-ECD. 3, 4, 1
• If plasma sampling was not supine, repeat after 30 minutes of recumbency. 2, 3, 4
• If borderline elevations persist after proper sampling and chromatographic assay, consider a clonidine suppression test to distinguish true-positive from false-positive results. 2

Clinical Decision Algorithm

For a patient on quetiapine with elevated metanephrines:

1. Do not discontinue quetiapine based solely on elevated metanephrines, as no causal relationship is established. 3

2. Verify sampling conditions: Was blood drawn supine for ≥30 minutes? Was urine collection complete and free of dietary contaminants? 2, 3, 4, 5

3. Check assay method: If immunoassay was used, repeat with LC-MS/MS or LC-ECD to eliminate cross-reactivity. 3, 4, 1

4. Assess clinical context: Physiological stress (ICU setting, acute illness) can elevate metanephrines independent of tumor or drug effects. 2, 3

5. If elevations are >4× upper limit of normal after proper sampling and chromatographic assay, proceed directly to imaging (CT or MRI) for pheochromocytoma localization. 2, 4

6. If elevations are borderline (1–4× upper limit) and clinical suspicion is low, adopt a wait-and-retest approach at 6 months; progressive increases suggest an enlarging tumor. 2

Common Pitfalls and How to Avoid Them

• Pitfall: Assuming quetiapine causes true physiological elevation of metanephrines.
  Solution: Recognize that the FDA warning refers to immunoassay cross-reactivity, not altered catecholamine metabolism; switch to chromatographic methods. 1, 3

• Pitfall: Failing to ensure supine positioning for plasma metanephrine sampling.
  Solution: Seated sampling alone can produce false-positives; always repeat with proper supine positioning if initial results are positive. 2, 3, 4

• Pitfall: Overlooking other anticholinergic or sympathomimetic medications the patient may be taking.
  Solution: Review the full medication list for tricyclic antidepressants, labetalol, midodrine, and over-the-counter acetaminophen. 2, 3, 6, 7

• Pitfall: Delaying pheochromocytoma work-up because the patient is on quetiapine.
  Solution: Do not delay imaging if metanephrines remain markedly elevated after proper sampling and chromatographic assay; quetiapine is not a contraindication to proceeding with diagnostic evaluation. 3

Additional Quetiapine Considerations

• Quetiapine has documented anticholinergic effects that can cause urinary retention, particularly in patients with low BMI, but this is unrelated to metanephrine measurement. 8, 9
• Quetiapine does not appear in the Endocrine Society's table of medications that interfere with catecholamine or metanephrine disposition. 3
• The drug's metabolic side effects (weight gain, dyslipidemia) are dose-dependent but do not involve catecholamine pathways. 10